Polygon Therapeutics

French tech company | Builders Republic

About

Biotech developing immunotherapies for cardiovascular disease — monoclonal antibodies that target the immune cells driving inflammation, starting with a candidate that limits heart damage and heart failure after a myocardial infarction, spun out of the Paris Cardiovascular Research Center.

Key facts

Status
Active
Sectors
Healthcare & Life Sciences
Latest stage
Seed
Founded
2021
Origin
Research spin-off
Registered office
Levallois-Perret
Region
IDF
Tracked rounds
2
Amount raised
7.5 M€

Operations

  • Seed · 2024
  • Pre-seed · 2021

Investors